Patients undergoing prophylactic central compartment dissection (PCLND) for papillary thyroid cancer (PTC) are often overtreated. This study aimed to determine if molecular fluorescence-guided imaging (MFGI) and spectroscopy can be useful for detecting PTC nodal metastases (NM) and to identify...
EMI-137
Filter news by category :
Results published by Investigator on Image-guided Surgery in Penile Squamous Cell Carcinoma Patients
21 May 2021 | Collaborations, EMI-137
This pilot study suggest that c-MET is a promising target for fluorescence-guided tumour identification, with the potential to improve margin assessment in pSCC. The c-MET targeted approach proved to be compatible with lymphatic mapping performed in the same patient using multicolor fluorescence...
Results from Phase II clinical development of EMI-137 published
02 Oct 2020 | EMI-137
The work carried ou as part of Phase IIb stage of development of EMI-137 has showed FME using EMI-137 appeared to be safe andfeasible within a 1- to 3-h dose-to-imaging interval. No clinicallysignificant differences were observed among the cohorts, althougha...
Edinburgh Molecular Imaging Commences Phase II European Cancer Trial
20 Sep 2017 | EMI-137
Novel Compound with Potential for Early Detection and to Guide Treatment of Colorectal Cancer Edinburgh, UK – 19 September 2017: Edinburgh Molecular Imaging (EM Imaging), the clinical phase biotechnology company focused on enabling image-guided therapy, announces it has commenced a pivotal Phase...
Edinburgh Molecular imaging Ltd awarded Innovate UK grant to qualify the role of EMI-137 in colorectal cancer lesion detection
09 Mar 2016 | Collaborations, EMI-137
Edinburgh Molecular imaging Ltd (EM Imaging) announced today that the company has received a SBRI Stratified Medicine Connecting the UK Infrastructure Phase I grant from the UK’s innovation agency, Innovate UK. The SBRI grant aims to accelerate and increase the development and adoption of...